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Abstract 
This Master of Science by Research thesis explores blood management strategies regarding 
hip and knee joint replacement surgery. 
I begin my work by exploring the background to why this is important, with a history of 
transfusion and joint replacement surgery. 
I then examine the evidence behind blood management strategies in arthroplasty and 
identify areas where the evidence is lacking. 
I present my two papers published and accepted for publication. 
I finish with a discussion of the limitations and what I learnt from my work. 
Including in the appendix is work I was involved in regarding blood management in joint 
replacement surgery but this was not my own original work so was not included within the 
main section of this text. 
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BACKGROUND 
Total joint arthroplasty is the operation of choice and a reliable option for end stage arthritis 
of the hip and knee. With a growing and aging population, the incidence of total hip and 
knee arthroplasty is increasing. According to the Australian National Joint registry, there was 
a 4.1% increase in total knee arthroplasty (TKA) performed in 2012 compared to 2011, and a 
92.4% increase since 2003. The number of total hip arthroplasty (THA) also increased by 12% 
from 2011 to 2012.i This is in keeping with a worldwide trend of increasing arthroplasty 
operationsii, iii 
 
Total joint arthroplasty surgery carries inherent risks.  Anaemia due to blood loss remains 
one of the major complications from joint replacement surgery, and is relatively common. 
Bierbaum et al reported transfusion rates of 57% and 39% for total hip arthroplasty and 
total knee arthroplasty respectivelyiv.  
 
Across the globe orthopedic surgery is responsible for the highest percentage of allogenic 
transfusions compared with other surgical specialties. These procedures account for 9.8% of 
all red blood cell transfusions. Elective orthopaedic surgery utilised the most packed red 
blood cells compared to other surgical specialties. The only branch of medicine where there 
was greater demand for allogenic blood transfusion   was haematology (33.6%)  v,vi. 
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Osteoarthritis is the main cause of arthritis requiring TKA and THAvii. As osteoarthritis 
increases with age, so too does the relative co-morbidities of the patient.viii Surgical patients 
with greater co-morbidities are known to be at an increased risk of peri-operative morbidity 
and mortalityix. Thousands of patients undergo joint replacement as an elective procedure. 
Therefore it is extremely important to improve the safety of this operation and reduce the 
potential complications to ensure that patients achieve the desired improvement in their 
quality of life and the costs of care associated with these elective procedures are minimised.   
 
This thesis will first evaluate the current evidence base for the current strategies employed  
by orthopaedic surgeons to achieve optimal blood transfusion management in total hip and 
knee arthroplasty. Following a review of the literature a series of prospective studies will be 
presented that aim to identify best practice in the operative management of allogenic blood 
transfusion for patients undergoing total joint arthroplasty. 
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INTRODUCTION 
a) History of arthroplasty 
 
Total hip arthroplasty has been identified as the gold standard to which other joints 
replacements have followed. It seems fitting to describe the history of the development of 
the total hip arthroplasty. 
 
Joint arthropathy has been around for thousands of years x. Osteoarthritis is the most 
common aetiology of these arthropathies xi. 
 
In the pre anaesthetic era, amputation was the operation of choice for traumatic joint 
injuries suffered by causalities of war due to ease and speed of operation. Surgeons such as 
Henry Park (1744-1831) who worked at The Royal Infirmary advocated for joint excision 
creating an arthrodesis, ‘thereby obtaining a cure by means of Callus’.xii 
 
White, in 1821xiii and Barton, in 1826xiv, both tried to manipulate the fusion of joints and halt 
the loss of movement by applying early motion to the excised area to create a pseudo-
arthrosis. Those who survived the surgery however eventually went onto fusion at a later 
time. 
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A Frenchman named Léopold Ollier xv  created worldwide interest in interpositional 
arthroplasty through the use of unfixed adipose tissue. Others tried different materials- 
both foreign and native. The first interpositional material to resemble today’s implants was 
the use of an ivory ball and socket joint fixed to bone by nickel screws in 1891 by 
Themistocles Glück of Berlin.xvi  
 
After failed attempts with other materials, Smith Peterson in 1937, with the help of a dental 
colleague, used Vitallium to produce good, reliable 10 year clinical results in moulded 
interpositional arthroplasty. xvii 
 
Parallel with the aforementioned interpositional arthroplasty were further attempts at 
prosthetic hip arthroplasty. The Frenchman Delbet, (1861-1925) used rubber in 1919; 
Groves an Englishman tried ivory in 1927; and the Judet brothers trialled acryclic in 1948. All 
these attempts failed due to material wear. xviii 
 
The classification of wear includes; adhesive wear, abrasive wear, third party wear, 
volumetric wear and linear wear. The common mechanism for each of these types of wear 
was the formation of debris. The foreign materials introduced into the hip joint lead to the 
recruitment of macrophages who through Rank ligand interactions induced osteoclastic 
activity and subsequent osteolysis or loss of bone stock. Prosthesis micromotion in turn 
increased wear and debris disseminated throughout the joint space further propagating 
osteolysis and consequent prosthesis failure .xix 
Not all pioneers of joint arthroplasty followed the same direction. It is of interest to note 
that major developments in excisional arthroplasty still occurred throughout this time. In 
1928 the eponymous Girdlestone procedure involving the resection of the femoral neck and 
head was popularised for treatment of infection and continues to be the fall-back option in 
failed arthroplasty revisions today.xx 
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Other noteworthy developments included the use of a metallic hemiarthroplasty by Moore 
and Bohlman in 1940 xxi and the use of acrylic bone cement for fixation by Haboush in 
1952xxii.  
 
Focus must turn to the father of joint arthroplasty- Sir John Charnley. His significance to the 
field can be learnt from the manner in which he developed the answer to his original 
question. 
‘The cart has been put before the horse; the artificial joint has been made and used, and 
now we are trying to find out how and why it fails.’ xxiii 
 
After an already distinguished surgical career, Charnley in 1949, at age 38, set up a hip 
centre through which he sought to answer the aforementioned statementxxiv. The answer 
came through his low friction arthroplasty. By reducing the size of the femoral head to 
22.2mm he reduced the torque transmitted from the head to the acetabulum. This is 
compared to Muller 30mm, Mckee-Farrar 41m and Weber 42mm designs. He believed any 
smaller would increase dislocation. xxv This counterintuitive solution was due to the fact that 
he speculated that a smaller femoral head size in the prosthesis would lead to reduced 
production of debris and subsequent osteolysis and thus, he hoped, would increase the 
longevity of his prosthesis compared to the others that were in contemporaneous use. 
 
The next advancement by Charnley came through choice of material. He began by using 
polytetrafluoroethylene(PTFE) as the acetabular shell. Laboratory data differed from in vivo 
results. On review of the first 300 cases, PTFE induced a significant foreign body reaction, 
with increased wear rates.xxvi Charnley demonstrated the answer as to why this occurred, 
through experimenting on one’s self, and in doing so explained the basis for osteolysis. 
Osteolysis is the loss of bone stock due to foreign body reaction to wear particles.xxvii 
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Ultra high molecular weight polyethylene was then inserted on the acetabular side in 1962 
and has for decades now continued to be used because of its excellent wear propertiesxxviii 
 
The third reason for Charnley’s legacy came through the development of proper 
understanding of acrylic cement’s role in total joint arthroplasty. While it had been used 
previously, Charnley understood its role not as glue but as a grout, leading to a tighter fit 
and greater area of implant to bone fixation.xxix 
 
Charnley ‘s Low Fraction Arthroplasty resulted in a 0.21% revision rate (excluding infection 
and periprosthetic fracture) for loosening at 10 years compared with Muller’s 10 % revision 
rate at ten years.xxx 
Engineering advances in implant design have continued, aiming to reduce complications, 
such as peri prosthetic fractures and revision surgery. This has mainly occurred through the 
development of cementless prostheses and improvements of prosthetic materials, 
especially the bearing couples.xxxi 
 Total knee arthroplasty followed a similar pre implant surgical path to the hip, as previously 
mentioned, with excisional and interpositional arthroplasty. Following on from Charnley’s 
success with total hip arthroplasty with polyethylene as a bearing surface and acrylic 
cement for fixation, total knee arthroplasty started to develop into a successful operation in 
the 1970s with the total condylar prosthesis. xxxii 
 
Previously to this knee replacement suffered from high failure rates with the constrained 
hinged prosthesisxxxiii. Gluck used Ivory in 1891 to produce a hinge joint replacement. 
 
In the 1970s total knee arthroplasty separated into two main philosophies; anatomical vs 
functional. 
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The anatomical approach revolved around preserving both cruciate ligaments to preserve 
femoral rollback and rotation, and was initiated by Gunston with the polycentric kneexxxiv. It 
was deemed too difficult for most surgeons to do well. It was also believed that the cruciate 
ligaments needed to be resected in order to correct the deformity. Further to this the 
complex nature of individual condylar anatomy was argued as too hard to surgically 
reproduce. 
 
In contrast, the functional approach removed at least the anterior cruciate ligament and 
provided a single femoral condyle to roll in a single tibial trough. This allowed for increased 
contact area between the femur and tibia, which reduced point stresses and subsequent 
wear. The single femoral component also increased the area for cementation between the 
prosthesis and bone, to improve fixation (compared with separate medial and femoral 
condyles). An example of a functional TKA was first popularised with the Freeman – 
Swanson prosthesis.xxxv 
 
The next differentiation in TKA design, which continues today, is posterior cruciate (ligament) 
retaining, versus posterior cruciate (ligament) substituting. Posterior Cruciate substituting 
was popularised by Insall. These designs are characterised by excision of the native posterior 
cruciate ligament and substitution with a post and CAM. xxxvi 
 
Implant design advancement was followed by a greater understanding of the importance of 
surgical technique in outcome. Flexion and extension balancing was described by Freeman 
and expanded by Insall to improve patient range of motion and stability. xxxvii,xxxviii 
 
Over the years different techniques have been developed to improve implant alignment. 
These include intra-medullary vs extra-medullary jigs, computer assisted navigation, and 
patient specific instrumentation. 
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b) Transfusion History  
 
While there are varying reports of blood transfusions throughout history, the first cannot be 
thought of as occurring before Harvey first described arterial and venous blood flow in 1628. 
There are reports of transfusion prior to this, however blood was mainly utilised via 
ingestion and medicinally. The basis for this usage was Hippocrates’ theory of humors. Blood 
being one of the four humors considered necessary in the appropriate balance to prevent 
disease. Initial transfusions involved animal to humans.xxxix Transfusion had limited clinical 
scope due to transfusion reactions with ABO incompatibility unknown at the time.  
 
Blood transfusion first became feasible and successful at the beginning of the 20th century. 
Landsteiner discovered ABO blood groups in 1901 to make blood transfusion biologically 
compatible. In 1907 Reuben Ottenberg performed the first blood transfusion using blood 
typing and cross-matching.xl Prior to this discovery, blood transfusions were associated with 
a 50% or greater mortality rate and were not considered safe medical practice.xli There were 
of often haemolytic reactions that were not understood. Initial blood transfusions were 
immediate from the donor to the recipient. The discovery that anticoagulation of  blood 
donations could allow for collected blood to be refrigerated and stored meant that the 
donor did not have to be present for the transfusion to occur. 
 
The advent of World War I meant that there was an exponential increase in the demand for 
the administration of rapid transfusions on the battlefield. Oswald Hope, a volunteer 
physician from USA, created the first known blood bank, changing practice from direct or 
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near same time transfusions, showed that a dextrose-citrate solution xiii would allow for the 
storage of blood for up to 26 days in glass vials.xlii 
 
The need and use of transfusion continued into World War II. Blood transfusions during the 
world wars saved many lives and the risks of the procedure were not appreciated. The 
development of joint surgery and other elective surgery is becoming a more commonplace 
procedure in the period after world war two meant that the clinical indications for blood 
transfusions were quite liberal by today’s standards. 
 
In the civilian surgical setting Adams et alxliii proposed in 1942, the 10/30 rule as the 
standard transfusion trigger. This translated to a haemoglobin concentration of 10 g/dL and 
haematocrit level of 30% being the pre operative minimum and to transfuse any patient 
below this level regardless of symptoms. Adam’s rationale was that anaemia affects the 
oxygen carrying capacity of blood and this subsequently would lead to insufficient oxygen to 
tissues. The scientific rationale to a haemoglobin of 10 g/dL was then suggested as the 
optimal haemoglobin concentration xliv.  
 
Adam’s obstetric paper became the foundation for liberal transfusions being the main stay 
of practice.  It wasn’t until after this time that the hazards of transfusion became more 
apparent. Such problems as the risk of blood borne infections like hepatitis and then in the 
1980s HIV. As a result of these and other non-infective risks associated with transfusion 
today the national blood authority of Australia sets a restrictive transfusion trigger; 
haemoglobin of 10g/dL as the maximum haemoglobin for patients suffering symptomatic 
anaemia, and 7g/dL as the objective value for transfusionxlv . The National Institutes of 
Health 1988 consensus conference report on red cell transfusion was one of the first to 
question this liberal transfusion strategy.xlvi 
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While hepatitis was a known adverse event from blood transfusion, it wasn’t until 1963 that 
the ‘red antigen’ or ‘Australian(au) antigen was discovered xlvii . This antigen is now 
recognised as the Hepatitis B surface antigen. In 1970 the National Institute of Health 
implemented a screening program for hepatitis B surface antigen, reducing hepatitis rates 
by 70%.xlviii Hepatitis C donor screening was introduced in the 1990s.xlix With the advent of 
screening systems, hepatitis incidence rates dropped from 30% pre 1970, to 10% in 1980s to 
a rate today that is estimated to be between 0.0001-0.0002 %l 
 
1981 saw the first case report of what is now known as HIVli.  The importance of adequate 
screening of donors for Hepatitis prevention became evident when it was realised that 90% 
of haemophiliacs had become infected with HIV prior to this initial case report.lii Screening 
tests now bring the incidence risk down to a similar rate as that of hepatitis, one per one to 
two million. 
 
In addition to the transmission of infections from the donors to the recipients blood 
transfusions can cause harm to patients through causing sepsis caused by bacterial 
contamination. The storage of packed red blood cells in sterile glass containers and 
refrigerators largely reduced bacterial contamination. liii Bacterial sepsis due to a blood 
transfusion is approximately one in five hundred thousand incidence. This is largely due to 
skin flora.liv 
 
Transfusion is now only part of today’s blood management strategies.  It is now important 
to review the evidence surrounding these other practices involved in blood management. 
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Literature search 
The national blood authority of Australia has released guidelines with regard perioperative 
blood management in patients undergoing surgery.lv They carried out a systemic review of 
blood management strategies involved in surgery. It was my initial goal to review the 
guideline’s suggestions and see how they relate to orthopaedic literature. 
 
Liberal vs restricted transfusion. 
 
As discussed in the introduction and history of transfusion, packed red blood cells were 
transfused to patients without hesitation in the post operative period to maintain a 
haematocrit of greater than 30, or haemoglobin of greater than 100g/L. Increasing concerns 
have been raised regarding the efficacy and safety of transfusion, as a result a more 
cautious, or restricted approach is now taken. The guidelines state ‘patients should not 
receive a transfusion when the haemoglobin level is ≥100 g/L. In postoperative patients 
with acute myocardial or cerebrovascular ischaemia and a haemoglobin level of 70–100 g/L, 
transfusion of a single unit of RBC, followed by reassessment of clinical efficacy, is 
appropriate’.   We now review the literature addressing the question of morbidity and 
mortality associated with transfusing with a liberal compared to a restricted transfusion 
trigger. 
 
With regards to the orthopaedic literature there has been substantial literature considering 
when is the appropriate time to recommend a blood transfusion to a post operative patient. 
A small pilot study examined hip fracture patients and showed no difference in length of 
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stay, 30 or 60 day mortality in patients given packed red blood cells once their haemoglobin 
was less than 100g/dL (liberal) vs those given a transfusion when symptomatic with a 
haemoglobin of less than 100 g/dl (restrictive).lvi 
 
Another study utilised the same transfusion trigger groups as above with a different hip 
fracture population. There were more cardiovascular events and greater mortality in the 
patients transfused when their haemoglobin was less than 100 (liberal) compared to the 
group transfused when symptomatic (restrictive), and no difference in functional scores or 
length of stay.  These included arthroplasty patients as a treatment option for hip fracture.lvii 
 
When we review patients from an exclusively elective arthroplasty population setting, it was 
shown that there was no difference in silent myocardial infarctions or days to discharge 
between liberal and restrictive transfusion groups during the post operative period.lviii 
 
Effect of red blood cell transfusion on patient outcomes 
Mortality- In cardiac patients there has been shown to be an increased mortality rate in 
those who receive autologous transfusions lix. In non cardiac surgery patients, the answer is 
not as clear cut. The  referenced study in the guidelines is a case controlled study of 229 hip 
fracture patients that showed an increased mortality in those who received transfusion of 
packed red blood cells after 90 days. lx A further literature search outside these guidelines 
revealed a study that demonstrated a similar finding, but on multivariable analysis the 
increased mortality is no longer true after accounting for other patient variables such as 
increased comorbidities(measured through ASA status) and age. lxi This multivariable result 
demonstrates the difficultly in inferring causality to mortality from transfusion due to 
confounders.  
 
 19 
 
No direct arthroplasty studies have been identified that have demonstrated any impact on 
mortality by having a blood transfusion. 
 
With time there has been shown to be increased morbidity directly related to transfusion. 
While the risks of reactions to the blood infused, along with contamination with viral or 
bacteria is well known, transfusion of blood has a systemic immune-modulatory effect on 
the body. If we now look at the morbidity related to transfusion in the post operative period. 
In an elective arthroplasty setting, it has been shown in a prospective study involving 444 
patients that transfusion is associated with an increased risk of wound infection, and 
subsequently an increased length of hospital stay in patients undergoing total hip 
arthroplasty lxii. In a hemiarthroplasty group of 290 patients, transfusion appeared to be 
correlated with superficial wound infection, urinary infection and pneumonia. lxiiiOne of the 
studies utilized by the guidelines demonstrated that non cardiac surgical patients have 
adverse morbidity as the result of transfusion. 9.6% of the 6301 non-cardiac surgical 
patients were orthopaedic patients. Consider as part of this group, those receiving blood 
transfusion had a higher rate of pneumonia, however the orthopaedic subgroup was not 
evaluated on its own.lxiv 
 
A further search of the literature outside the guidelines identified a cohort of 687 geriatric 
hip fracture patients and the only statistically significant complication associated with 
packed red cell transfusion was urinary tract infection. lxv The breakdown of surgical 
treatment- e.g. arthroplasty vs open reduction internal fixation, was not known. 
 
An increased length of hospital stay is associated with a higher cost of admission. In addition 
to the elective hip arthroplasty setting above lxvi, the guidelines also demonstrate there to 
be an increased readmission rate in hip fracture, however no patient was treated with a 
total hip arthroplasty and there was no difference in transfusion rates in those treated with 
hemiarthroplasty. lxvii  Further literature review outside the guidelines revealed a 
retrospective study of 2,104 total hip arthroplasty patients that showed red blood cell 
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transfusion to be a risk factor for length of stay regardless of haemoglobin difference. This is 
independent of other factors such as age and warfarin/heparin(vs aspirin) which were 
shown to be other risk factors.lxviii 
 
 
Pre operative anaemia 
Having a lower haemoglobin level prior to surgery is known to be an independent predictor 
of morbidity and mortality in non cardiac surgery patients.lxix lxx Pre operative anaemia is 
also the biggest risk factor for allogenic transfusion in joint arthroplasty patientslxxi, and with 
that comes the subsequent risk of adverse events associated with allogenic transfusion 
previously identified. 
  
It therefore seems logical to improve preoperative haemoglobin levels. Methods to improve 
haemoglobin levels preoperatively include iron therapy and erythropoietin. Iron is needed in 
the synthesis of haemoglobin. Erythropoietin is a hormone naturally produced by the 
kidneys, which stimulates erythropoiesis/red blood cell production. 
 
Iron and Erythropoietin- The guidelines suggest use of Iron therapy in patients with low 
ferritin and erythropoietin as well as iron in patients with anaemia of chronic disease. 
 
A cohort study of 156 patients treatment with ferrous sulphate 256mg / day with 
combination vitamin C(enhances absorption) for 1 month preoperatively reduces 
transfusion rate for non anaemic patients in an orthopaedic population.lxxii 
 
Erythropoietin has shown to be successful in improving; 1) mean preoperative haemoglobin 
and 2) post operative haemoglobin with reduced transfusion rates in the eight studies that it 
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was combined with Iron therapy in patients undergoing the following orthopaedic 
operations; hip fracture, hip and knee joint arthroplasty surgery.lxxiii 
 
 
 
Effect of Perioperative cessation of medications 
Patients presenting for joint replacement are often elderly. With this increasing age there is 
an increased number of comorbidities in these patients presenting for joint replacementlxxiv. 
Some medications to treat these co morbidities, such as warfarin, aspirin and clopidogrel, 
affectively reduce the effect of the clotting cascade. I will now review these medications and 
their effect on blood loss in surgery. 
 
Warfarin is a medication which inhibits the extrinsic pathway of the clotting cascade used in 
the treatment of disease such as atrial fibrillation, venous thrombosis and heart valves 
which are associated with an increased risk of thrombotic diseaselxxv. The guidelinelxxvi 
recommends the cessation of warfarin for procedures with an estimated large volume blood 
loss but it can be continued for arthrocentesis, cataract surgery, upper gastrointestinal 
endoscopy or colonoscopy (with or without biopsy), as morbidity and mortality were 
unaffected when warfarin was continued. lxxvii Current recommendations suggest assessing 
individual thrombotic risk and adjusting perioperative bridging therapy based on it. CHEST 
physicians guidelines, where patients are risk stratified into high risk(>10% annual 
thromboembolic risk), medium(5-10% annual thromboembolic risk) or low risk(<5% annual 
thromboembolic risk). All groups cease their warfarin 5 days preoperatively. High risk 
patients are managed with bridging therapy where Enoxaparin is started to maintain 
therapeutic anticoagulation peri operatively where low risk patients are not. Warfarin is 
restarted 1-2 days post operatively once haemostasis is adequate.lxxviii 
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Data from outside the Australian blood Bank perioperative guidelines suggest bridging 
therapy has been shown to increase post-operative stay and cost of stay when the patient’s 
warfarin is restarted.lxxix There have only been two other studies (Rhodes et al lxxxand Chana 
et allxxxi ) that have investigated the safety of continuing Warfarin in patients undergoing 
TKA. 
 
Rhodes et al performed a retrospective study of 39 warfarinised patients undergoing TKA 
and found no increase in the rate of haemorrhage for patients on continuous warfarin. The 
second study by Chana et al was a case series of 24 patients on continuous warfarin 
undergoing TKA and reported no major haemorrhage and only one minor wound problem. 
Chana et al reported mean pre-operative INR of 2.2 and a mean change in INR of 0.4. 
Rhodes et al also reported mean pre-operative INR of 2.1 and a mean change in INR of 1.2. 
 
Clopidogrel –is an antiplatelet medication commonly used in the prevention of recurrent 
transient ischemic attacks, strokes and coronary artery disease. It’s safety in surgery is not 
certain from the guideline’s recommendations as only one non cardiac study was identified 
that involved general surgical patientslxxxii. It was a small cohort study comparing those who 
received clopidogrel within 7 days of surgery vs greater than 7 days to surgery and there 
was no statistically significant difference found. Reviewing literature from outside the 
guidelines  demonstrated two small series which showed no increase in blood loss or 
transfusion in hip fracture patients.lxxxiii, lxxxiv 
 
Aspirin – is another antiplatelet medication used largely in the treatment of coronary artery 
disease. The guidelines recommend the cessation of aspirin prior to orthopaedic surgery if it 
does not pose a cardiovascular risk. This is on the premise that there was increased 
incidence of perioperative bleeding while on 100mg of aspirin, but the severity of the bleeds 
was not increased. Retrospective data shows a mean time between discontinuation of 
aspirin and complications as 8.5 days for acute coronary events and 14.3 days for 
cerebrovascular events. lxxxv 
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Utilisation of anti-fibrinolytics in Arthroplasty 
The most common anti-fibrinolytic agent in use is tranexamic acid. It is a lysine analogue 
which competitively inhibits the conversion of plasminogen to plasmin. Plasmin breaks 
down fibrin. Fibrin is the final product in the clotting cascade, acting in unison with platelets 
to form the haemostatic thrombus.  In the national guidelines discussing orthopaedic 
administration of tranexamic acid, it was only considered as IV administration and no dose 
recommendations were given within the national guidelineslxxxvi. There is no evidence for an 
increased incidence of myocardial infarction with unclear advice on the effect on 
thrombosis and stroke. This is based on a Cochrane review whose objective was to examine 
the evidence for the efficacy of aprotinin, tranexamic acid, and epsilon aminocaproic acid in 
reducing perioperative blood loss and allogeneic blood transfusion, and the evidence for any 
effect on clinical outcomes such as mortality and re-operation rates.lxxxvii  
 
When examining the orthopaedic systematic review a dosing regimen of 10-15mg /kg IV was 
most common (max 1g) at induction. The relative risk for transfusion was 0.47 with a mean 
difference of 393ml in TKA and 639ml in THA vs placebo. 
 
There was found to be no increased risk of thromboembolic disease, but few studies 
objectively looked for it, with only one study performing venous ultrasound on day 21. 
Given most of the DVT screening in the Cochrane orthopaedic review article occurred at day 
3-5, if done at all and it cannot be safely assumed that there is no increased risk of venous 
thromboembolism, as it was screened for at too early a stage. The one study which did 
ultrasound on day 3 and 21 failed to show a difference in DVT incidence, but it only involved 
a study population of 40 patients. lxxxviii 
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A Further literature search demonstrated one study that has shown topical administration 
to be more effective when given at the same dose of 1.5g as intravenous in total knee 
arthroplasty. lxxxix 
 
 
 
DVT prophylaxis 
Continuing on the theme of thromboembolic disease post arthroplasty, although not 
included in the perioperative blood management guidelines, DVT prophylaxis is a 
contentious issue and deserves discussion. The natural history of DVT post arthroplasty is 
that the majority of DVTs begin and resolve within the first 3 days post operatively xc but 20% 
develop in previously thrombus free veinsxci. 61% occur after day 3 with 9% occurring after 
the first week. xcii75% develop in the operated leg. xciii 75% of fatal post operative PEs occur 
between days 3-7 post operatively.xciv It would therefore have been optimal to evaluate 
objectively for DVT within the first 7 days post operatively of the tranexamic acid studies.  
 
However, groups such as Kim et al, who showed a 20% and 41% incidence of DVT in Korean 
hipxcv and kneexcvi arthroplasty patients respectively, at day 7 without thromboprophylaxis, 
also demonstrated that without treatment there was a 100% resolution of DVTs in this 
patient group at 6 months with no objective evidence of pulmonary emboli, questioning the 
significance of DVT in this population. Care should be taken when applying these results to 
western patients due to genetic differences and associated co-morbidities seen in Western 
populations which may make the Korean studies falsely reassuring . Symptomatic DVTs 
present differently, with large population studies suggesting an incidence of between 1.2xcvii 
- 2.8%xcviii, and they present much later in time. The mean presentation was shown to be at 
a mean of 7 to 16 days post operatively for total knee replacement, and, 17 to 27 days post 
operatively for total hip arthroplasty from large data studies from American xcix  and 
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Scandinavian c  populations respectively. This has resulted in longer duration 
thromboprophylaxis regimes to extend beyond the period of hospitalisationci.  
 
While the goal of prophylaxis has been to decrease the incidence of DVTs and in so doing 
lead to a decrease in the subsequent incidence of pulmonary embolus and fatal pulmonary 
embolus; to date there has been no reduction in mortality able to be attributed to this 
intervention.  cii. The all case mortality rate has been shown to be lower with the use of 
aspirin compared with low molecular weight heparin and warfarin, with no statistically 
significant difference in pulmonary embolus or fatal pulmonary embolus rates between 
chemical thromboprophylactic regimesciii. 
 
As a result the Australian Arthroplasty society now advocates for low dose aspirin as part of 
a multimodal thromboprophylactic regime in low risk patients(i.e. no previous 
thromboembolic disease). civ 
 
The focus of this thesis is on perioperative blood transfusion management. Low Molecular 
weight heparin and warfarin(to a lesser extent) have a higher volume of blood loss and 
increase the risk of transfusion relative to aspirin.cv 
 
With this increased blood loss there has been a higher incidence of wound complications, 
namely increased drain volume, superficial infection and deep infection requiring surgery in 
the warfarin group vs. aspirin.cvi Other studies have shown the method of thromboembolism 
prophylaxis has an effect on wound complications. Potent chemoprophylaxis has been 
associated with higher rates of wound drainage and other post-operative complications.cvii It 
has been demonstrated that there is a clear association between anticoagulants and 
periprosthetic joint infection after hip and knee replacementcviii. Patients treated with low 
molecular weight heparin vs aspirin had a longer time to a dry surgical wound. Each day of 
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prolonged wound drainage increased the risk of wound infection by 42% following a total 
hip arthroplasty and by 29% following a total knee arthroplastycix. 
 
The time to initiate the chemical thromboprophylaxis is a balance between the prevention 
of thromboembolic disease and the risk of bleeding and subsequent morbidity risks.  The 
optimal time therefore balances this risk, medications should be started with the target 
being the achievement of adequate anticoagulation at a circulation 8 hours post operatively. 
cxThis allows for haemostasis of small vessels to be achieved during the operation and 
therefore reduced intra-operative blood loss. For example, in the case of low molecular 
heparin, it should be injected subcutaneously 4 hours post operation to reach effect at 8 
hours, vs. 7 hours for unfractionated heparin.cxi 
 
As indicated in the Australian Arthroplasty society guidelinescxii the potential morbidity 
associated with the increased risk of blood loss and wound complications needs to be 
balanced against the risk of DVT and pulmonary embolus on a patient-by-patient scenario.   
 
Pre operative autologous donation 
One idea that appears to have face validity is to have patients receive their own blood back 
during an operation after donating it pre-operatively.  This method has gained favour 
because of the reported cases of transfusion acquired HIV and Hepatitis that occurred in the 
1980s prior to the universal screening of blood donors. It was thought that by using one’s 
own haemoglobin that you would be able to eliminate the risk of transmission of 
transfusion acquired infections and that there might be scope to be more liberal in its usage 
as it was the patient’s own blood. 
 
However, this approach did not lead to the hoped reduction in perioperative morbidity and 
indeed was found to lead to an increase in adverse outcomes. The donation of the blood 
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leads to a decrease in the pre operative haemoglobin in patients, which in turn, leads to an 
overall increased rate of transfusion, albeit autologous. Aside from the lack of clinical 
benefit autologous transfusion was found to be an expensive procedure. There is a high rate 
of wasted blood units with autologous donation, ranging from 40% to 56%, and therefore it 
is no longer deemed to be cost effectivecxiii.  Furthermore, the total cost of pre autologous 
donation is more expensive than allogenic transfusions cxiv and reported to be approximately 
135% of homologous units due to logistical and tracking issues. Pre-operative autologous 
donation is also not free of risk with administrative error, the major cause of significant 
harm with the potential for the wrong blood being returned to the patient. cxv 
 
Based on two Cochrane reviewscxvi, cxvii which did not comment on any effect on mortality, 
morbidity or length of stay, the national blood authority perioperative guidelinecxviii stated 
that Autologous transfusion is not recommended. The Australian Blood Bank consequently 
currently imposes a cost to patients if they wish to utilise pre-operative autologous 
donation.cxix 
 
Operative factors 
Depending on the surgeon, there are different variations in the approach in gaining access 
to the joint and completing the joint replacement. The choice of approach is often due to 
the training and experience of the surgeon. 
 
Approach to the knee joint is largely the same, with most surgeons utilising a medial para-
patellar approach as their arthrotomy. 
 
The hip can be approached through anterior, lateral or posterior incisions, the posterior 
approach being the most commoncxx. A systematic review comparing the anterior and 
posterior approach found a trend towards lower blood loss in the posterior approach but 
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this was not found to be statistically significantcxxi, although individual studies suggest a 
200ml total blood loss less in the posterior vs anterior approachcxxii. A comparison between 
lateral and anterior approaches found a significant difference between pre operative and 
day 1 post operative haemoglobin to be higher in the lateral approach(3.5 vs 3.1 g/dL )cxxiii 
However, blood loss is not an absolute reason to choose an approach. Surgeon training 
often dictates which approach is utilised by a surgeon, and there is a significant learning 
curve when learning a new technique. This has correlated to increased operative times and 
increased blood loss is those learning the anterior hip approach.cxxiv 
 
It has been shown that a surgeon’s experience level effects the blood loss during surgery. 
Blood loss has been shown to be less in total hip arthroplasty for surgeons with a higher 
volume of cases and shorter operative time.cxxv 
 
Blood in the surgical field can make visualisation difficult during surgery. Some surgeons use 
a Tourniquet to reduce blood flow of the area being operated on, commonly use in total 
knee arthroplasty. Others argue that by not using a tourniquet they are better able to 
identify larger blood vessels, ligate them and thus reduce the total overall blood loss (via 
decreased post operative blood loss). Nonetheless,  the guidelinescxxvi advocate for the use 
of a tourniquet where possible. However in relation to total knee arthroplasty different 
meta analyses have concluded different views regarding intraoperative and total blood loss. 
Half of the recommendations state no difference in both intra and total blood loss where as 
the other half advocate that it has a protective effect.cxxvii,cxxviii, cxxix It would appear that 
there is no consensus with respect to the use or otherwise of the tourniquet . 
 
Any joint replacement relies on fixation between the newly implanted prosthesis and the 
bone. There are Cemented and Uncemented prostheses. Cemented prostheses have been 
shown to result in a lower blood loss. cxxxThere are pros and cons to any method of fixation 
and blood loss is not an absolute indication for choice of fixation. 
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Anaesthetic related 
While not in direct control of the anaesthetist, positioning of the patient for a surgical 
procedure is done in a way to allow best exposure for the surgeon but still allowed the 
anaesthetist to monitor and intervene on the cardiorespiratory functions as needed. Lateral 
positioning in total hip arthroplasty has been shown to reduce blood loss as postulated by 
reduced venous engorgement due to the effect of, gravity.cxxxi  
 
Anaesthetic is the process of rendering a patient ‘without sensation’ for a procedure. It 
involves using agents, which produce a combination of analgesia, lack of memory, 
unconsciousness and muscle relaxation, all to a varying degree depending on the patient 
and procedure to be performed. Different Anaesthetic types can effect blood loss. Spinalcxxxii 
and regionalcxxxiii anaesthesia have both been shown to be effective at reducing blood loss in 
total hip arthroplasty but do not impact on blood loss that occurs during a  knee 
replacement. 
 
It is the anaesthetist’s role to monitor and maintain the patient’s cardiovascular and 
respiratory function throughout the anaesthetic period. Intraoperative permissive 
hypotension- supports the use of the lowest blood pressure that still maintains cerebral 
perfusion in an effort to decrease surgical blood loss. The guidelines suggest the use of 
intraoperative hypotension in patients who are not at an increased risk of cerebrovascular 
or cardiovascular events. Support for this approach is evidenced by a systematic review that 
demonstrated reduced blood loss and transfusion requirements with the use of 
intraoperative hypotension, with a mean 286ml less of estimated blood loss in the 
hypotensive(MAP mean 60mmHg) vs control(MAP mean 90mmHg) groups. cxxxiv 
 
Anaesthetic agents are known to produce hypothermia to the unwarmed surgical patient. A 
Grade A recommendation is that there should be prevention of hypothermia during surgery 
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cxxxv.  Hypothermia in anaesthesia is not clearly defined by the national blood authority 
guidelines and varies between studies. Some suggest maintaining the temperature greater 
than 35°C is adequate, whereas others suggest temperature should be maintained greater 
than 36°C.cxxxvi 
This is contrary to normal thermoregulatory physiology, as normal body temperature 
averages 37°C and is rarely < 36.5°C cxxxvii.Hypothermia during surgery is believed to be 
linked to adverse outcomes, such as an increased transfusion rate. There is no clear 
evidence that it has impacts on either the length of hospital stay or post operative 
haemoglobin. This recommendation is backed from data mainly relating to general cxxxviii and 
cardiothoracic surgery cxxxix. cxl. 
 
When looking at the orthopaedic literature, in particular arthroplasty, there is just one 
systematic review of three randomised control trials that have attempted to quantify the 
impact of changes in temperature in the theatre with the amount of intraoperative blood 
loss. The data from three studies on the effect of hypothermia and blood loss in total hip 
arthroplasty has produced inconsistent results. . 60(Schmied et alcxli), 50(Johansson et alcxlii), 
150(Winkler et alcxliii) evaluated patients with temperature differences of 1.5, 0.8 and 0.5°C 
between comparator groups. Schmied et al and Winkler et al demonstrated a significant 
difference with 480 and 147 ml less mean total blood loss in the warmer group , Johansson 
et al found no significant difference between the two groups. Retrospective data has shown 
that active warming reduces transfusion requirements in total hip and knee replacements, 
but this study failed to demonstrate a change in haemoglobin levels with treatment cxliv. 
 
At this point in time there is very limited data that supports the fairly strongly expressed 
views surrounding the impact of maintaining a warmer temperature to reduce blood loss 
during total hip replacement and no study has specifically attempted to evaluate its role in 
total knee arthroplasty 
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Intra operative and post operative cell salvage 
Cell salvage is a form of auto transfusion/ autologous transfusion, whereby red blood cells 
lost during or after the operation are collected and reinfused into the patient, in the hope of 
decreasing their overall volume and blood loss and subsequent risk of allogenic transfusion. 
  
The guidelines state that it reduces transfusion requirements- both incidence and volume. 
The guidelines are uncertain as to if it reduces morbidity, mortality or length of stay. 
 
Of the referenced articles one systemic review concluded that 96% of trials had poor 
methodology with poor randomisation. It also found cell salvage to be more effective in 
orthopaedic surgery than cardiac (RR 0.35 vs 0.82) in reducing autologous transfusion risk 
but no effect on length of stay and morbidity. Only one study involved over 200 patients, 
and two over 100 patients.cxlv 
 
In a meta-analysis which focused more on orthopaedic surgery, washed and unwashed cell 
salvage devices were found to be effective at  reducing allogenic transfusion risk with 
relative risk of 0.39 and 0.35 respectively. Cell salvage did not have any adverse events 
recorded, and the analysis did not comment on reducing mortality and length of stay.cxlvi 
 
A further search of the literature identified a systematic review of anaemia and patient 
blood management in hip and knee surgery. This study foundcxlvii that perioperative cell 
salvage decreased length of stay by 1 daycxlviii in total hip arthroplasty and 0.5 days in post 
operative cell salvage in total knee arthroplasty. cxlix  
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It is hard to give figures for cost effectiveness of cell salvage techniques. The total cost of 
allogenic blood needs to take into account direct and indirect costs. Direct costs include 
labour, equipment, infection tests, processing, inventory management, and compatibility 
tests in a mixed surgical population. Indirect: Discarded, crossover crossmatch, treatment of 
complications. Costs are normally presented as per unit of blood.cl 
 
A unit of packed red cells in Australia costs $346.86.cli 
 
No direct cost analysis exists for orthopaedic hip or knee arthroplasty surgery for cell 
salvage, and future cost analysis of it’s efficacy is the recommendation of a review paper on 
cell salvage in arthroplasty . Cost analysis needs to take into account increased hospital 
costs with increased length of stay associated with allogenic transfusion. Equally, if cell 
salvage is used routinely, cost benefit calculations needs to consider that not all patients 
receive returned blood and certain patient cohorts are likely not to require any sort of blood 
salvage measure. Across surgical specialties the national blood authority in it’s guidance for 
use of intraoperative cell salvage deemed it to be ‘cost effective when used appropriately. 
Deciding when to use cell salvage in either routine or at risk patients is yet to be explored. A 
recent study has questioned the routine use of blood conservation strategies in primary TKA 
and THA when contemporary anaesthetic and surgical techniques and transfusion triggers 
are used.clii 
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Hypothesis/Aims 
From the literature review, I wanted to contribute to a better understanding of orthopaedic 
arthroplasty and identify areas where there could be improvements in the understanding of 
what might be evidenced based best practice for managing intraoperative blood loss 
management. The search of the literature confirmed that there were two areas where there 
was an opportunity to study. The key questions I sought to answer through my research 
were: 
1) Do changes in intraoperative body temperature during anaesthesia impact on the 
amount of blood loss and need for blood transfusion during total knee and hip 
arthroplasty? 
 
2) What is the effectiveness of intraoperative Cell salvage during total knee and hip 
Arthroplasty? Does it’s use accurately estimate the amount of blood loss during the 
procedures and does this result in a reduced need for blood transfusion either intra-
operatively or post operatively?   
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Methods 
Over the course of my enrolment I completed two research papers that are currently under 
peer review and have been accepted for publication. Each of the next two chapters are the 
result of my efforts to answer these two critical questions that arose from the my search of 
the literature:  
 
Paper 1:   Blood loss in primary total knee arthroplasty—body temperature is not a 
significant risk factor—a prospective, consecutive, observational cohort study?  
The chapter that is presented is the manuscript that has been published in Journal of 
Orthopaedic Surgery and Research (2015). 
 
Paper 2: Analysis of the effectiveness of intraoperative cell salvage in primary total hip and 
knee arthroplasty 
The chapter that is presented is the manuscript that has been submitted to the Journal of 
Orthopaedic Surgery and is accepted for publication in 2016. 
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The methodology for each study is discussed in the methods section of both papers. 
 
Both studies entail many methods that were common to both papers. In the appendix i) I 
outline the procedures that were common to both studies in greater detail than what has 
been described in the journal articles. 
 
 36 
 
 
 37 
 
 
 38 
 
 
 39 
 
 
 40 
 
 
 41 
 
 
 42 
 
 
 43 
 
Title 
 
Intra-operative Red Cell Salvage in Primary Total Hip and Knee Arthroplasty 
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Intra-operative Red Cell Salvage in Primary Total Hip and Knee Arthroplasty 
 
Abstract 
 
Purpose 
The aim of our study was to ascertain if intra-operative cell salvage is effective in negating the need 
for allogenic transfusion in patients undergoing primary hip and knee arthroplasty.  
 
Methods 
The study comprises a retrospective analysis of 371 consecutive patients undergoing primary hip or 
knee arthroplasty with concomitant use of intra-operative cell salvage. The percentage of patients 
requiring allogenic transfusion despite cell salvage was the primary outcome. Other factors affecting 
transfusion risk were analysed. 
 
Results 
The overall transfusion rate was 16%. 24% of hips and 12% of knees received allogenic blood. 
Despite routinely utilising cell salvage in all cases, only 59% of hips and 63% of knees received 
returned red cells. Significantly greater blood loss occurred in the patients who were given returned 
red cells. Transfused patients had a significantly lower pre-operative haemaglobin, less intra-
operative blood loss and were less likely to receive cell salvage blood. Pre-operative haemoglobin 
less than 120 g/L, female gender, and age greater than 75 was associated with a higher risk of 
allogenic transfusion. Patients receiving allogeneic transfusion had a longer hospital stay and greater 
complication rate. 
 
Conclusions 
Intra-operative cell salvage reduces but does not eliminate the need for allogeneic blood transfusion 
in primary hip and knee arthroplasty. The efficacy of cell salvage is related to haematocrit and 
volume of the blood lost. Intra-operative cell salvage on its own is not effective in patients with a 
 45 
 
pre-operative haemaglobin less than 120g/L and should be combined with additional strategies such 
as correcting pre-operative anaemia. 
 
Keywords: Cell salvage, arthroplasty, blood management, transfusion. 
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Introduction 
Total hip and knee arthroplasty may result in substantial peri-operative blood loss, leading 
to post-operative anemia and rendering the patient at risk of requiring an allogenic blood 
transfusion. Bierbaum et al reported transfusion rates of 57% and 39% for total hip 
arthroplasty (THA) and total knee arthroplasty (TKA) respectively 1. Total joint arthroplasty 
and fracture surgery is responsible for the highest percentage of allogenic transfusions 
compared with other surgical specialties 2,3. 
 
Allogenic blood however is associated with risks to the patient, including disease 
transmission, hemolytic reactions, immunomodulation, hemodynamic overload, acute lung 
injury, and coagulopathy 4. Previous studies have demonstrated an increased risk of 
postoperative infection, length of hospital stay and mortality in patients who receive 
allogenic blood 5,6,7. Consequently, various blood conservation strategies have been 
employed in THA and TKA to reduce the need for allogenic blood.  
 
Pre-operative autologous donation does reduce allogenic blood requirement 8,9,10,11, 
however is associated with a high rate of unused blood and is not cost effective 12,13,14. The 
effectiveness of acute normovolaemic haemodilution in reducing transfusion need is 
debatable 15. Studies on the use of post-operative reinfusion drains report a risk reduction in 
allogeneic transfusion 16,17,18.  
Reinfusion drains however carry the potential for transfusion reactions as unwashed blood 
contains fibrin degradation products and other potential contaminants 19,20.  
The intra-operative cell salvage technique used at our hospital incorporates washing of 
blood collected during surgery prior to reinfusion. We favor this method of blood 
conservation as it causes minimal disruption to surgical workflow and removes biochemical, 
cellular and non-cellular debri such as activated clotting factors, fatty lipids, and bone 21,22. 
We have routinely used intra-operative cell saver with washed red cells in THA and TKA, in 
 47 
 
the belief it would eliminate allogenic blood transfusion requirement and improve patient 
outcomes. 
The primary aim of our study was to ascertain if intra-operative cell salvage is effective in 
negating the need for allogenic transfusion in patients undergoing primary THA and TKA, by 
determining the percentage of patients requiring allogenic transfusion and comparing this 
with traditional transfusion rates reported in the literature 1. The secondary aim was to 
identify risk factors predicting the requirement for allogenic transfusion in patients who 
underwent cell salvage and establish how to optimize the effectiveness of cell salvage. 
Whilst previous studies have already reported on the benefits of cell salvage in THA and TKA 
23,24,25,26,27,28, our study cohort is an updated review reflecting contemporary techniques in 
arthroplasty surgery including anaesthesia, surgical technique and individualization of 
transfusion trigger.  
 
Materials and Methods 
 
The study comprises a retrospective analysis of 371 consecutive patients undergoing 
primary THA and TKA with concomitant use of intra-operative cell salvage from January 
2010 to December 2011. From the currently available literature, similar studies have 
reported the proportion of patients requiring transfusion to be approximately 20%. 
Therefore, in order to obtain a 95% confidence interval, we calculated 246 patients would 
be required for sufficient power for the study. Ethics approval was obtained from the 
Hospitals Regional Ethics Committee. 
 
One surgeon performed all surgeries, using the same prosthesis, surgical technique and 
identical post-operative protocol in all patients. The hips were performed through an 
antero-lateral approach with the patient in the lateral position. Uncemented acetabular and 
femoral components were inserted in all patients, without use of a drain. The knees were 
performed through a standard medial para-patellar approach without tourniquet. Computer 
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navigation was utilized for alignment and preparation, and cemented femoral, tibial and 
patella components were used in all patients. An intra-articular drain on low suction was 
removed day 1 post operatively for the knees. All patients received enoxaparin 40mg daily 
for venous thromboembolic prophylaxis, commencing 4 hours post-operatively and 
continued for 14 days for TKA and 28 days for THA. Aspirin was continued through the peri-
operative period if the patient was already on the medication prior to surgery. 
 
Intraoperative cell salvage was performed in each case with the Haemonetics Cell Saver 5+ 
machine (Braintree, MA, USA).  The salvaged blood was washed and concentrated prior to 
reinfusion. Reinfusion was commenced in the recovery room and completed on return to 
the ward. Hemoglobin levels were checked day 1 post-operatively. Transfusion trigger was 
patient specific, based on recommendations by the National Blood Authority of Australia. 
Haemoglobin of less 80g/L was an absolute trigger and less than 100g/L with symptomatic 
anemia and significant co-morbidities a relative indication for transfusion 29. The relative 
indication for transfusion was based on the surgeon’s best judgment according to the 
patient’s symptoms and risk of complication such as myocardial events. 
 
Our primary objective was to ascertain if intra-operative cell salvage is effective in negating 
the need for allogenic transfusion in patients undergoing primary hip and knee arthroplasty, 
by determining the percentage of patients requiring allogenic transfusion despite cell 
salvage. Additional data collection included demographics, complications, days until 
discharge, and hemoglobin change from pre-operatively to day 1 post-operative. Blood loss 
was measured and calculated using three methods of cell salvage volume, post-operative 
drain volume in TKA patients, and the difference between pre-operative and post-operative 
hemoglobin. 
  
Results were described using proportions for binary variables, means and standard 
deviations for normally distributed variables and medians and inter-quartile ranges for 
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variables not normally distributed. We analysed using simple and multivariable logistic 
regression to determine predictors of need for transfusion. 
 
Results 
Demographics of the study cohort are summarized in table 1., including the proportion of 
patients in each category of pre-operative hemoglobin level. Eight percent of patients 
started with pre-operative hemoglobin less than 120g/dL, with the rate being 3 times higher 
in THA patients.  
The overall transfusion rate was 16%, with 24% of THA patients and 12% of TKA patients 
requiring allogenic blood despite intra-operative cell salvage. Our results demonstrate a 
statistically significant decrease in allogenic transfusion rates compared to the historical 
non-cell salvage population of Bierbaum. A summary of transfusion rate of the current study 
compared with previously published literature is presented in tables 2 and 3 for THA and 
TKA respectively. 
Blood loss outcomes for the 371 patients are shown in table 4. A pertinent finding is only 63% 
of knees and 59% of hips actually received returned red cells. Comparison of patients who 
received returned red cells with those who didn’t is displayed in table 5. Significantly greater 
intra-operative blood loss occurred in the cell salvage group, with a mean of 362.48mls 
compared to 156.15mls. Intra-operative blood loss ranged from 200mls to 1200mls in the 
salvage group, in contrast to 50mls to 350mls in the non-salvage patients. Only 9 patients, in 
whom salvaged blood could not be obtained, had intra-operative blood loss greater than 
200mls. From our data, a minimum of 200mls intra-operative blood loss is required to have 
sufficient volume to cell salvage. 
Table 6 compares patients who received allogenic blood transfusion versus patients who did 
not. Significantly, transfusion risk was reduced with greater intra-operative blood volume 
loss, higher pre-operative haemaglobin and if the patient received salvaged blood. Our 
philosophy was to use an individualized variable transfusion trigger. Mean post-operative 
haemoglobin in the transfused patients was 103.46g/L compared to 121.65g/L in the non-
transfused patients. The difference was statistically significant.  The post-operative 
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haemaglobin in patients who required allogenic blood ranged from 71g/L to 110g/L. 
Allogenic transfusion requirement significantly increased length of hospital stay and 
incidence of peri-operative complications. 
 
Using multivariable regression analysis, female gender, pre-operative haemaglobin less than 
120 g/L, and age greater than 75 years proved to be significant risk factors for requiring 
allogenic blood, despite the use of intra-operative red cell salvage. Results of the univariable 
and multivariable analyses are shown in table 7. Four patients in the study group had a BMI 
less than 20. All 4 of these patients required allogenic transfusion, however the numbers 
were too small to allow statistical analysis. 
 
Discussion 
 
An effective blood management strategy is one of a number of critical components required 
for the successful care of joint arthroplasty patients. Significant blood loss may occur 
following THA and TKA, resulting in post-operative anemia, hindering patient recovery or 
leading to the need for allogenic blood transfusion. Allogenic transfusion has been shown to 
be detrimental to patient outcome and recovery following joint arthroplasty surgery 30,31,32.  
 
Intra-operative red cell salvage re-infuses fresh blood and avoids problems with storage of 
red blood cells seen with autologous pre-donation and allogeneic red blood cells. This 
translates to more efficacious oxygen carrying red blood cells with a higher mean 
erythrocyte viability 33 and increased preservation of 2-3 diphosphoglycerate 34. The 
technique also incorporates washing the blood loss volume, thereby removing contaminants 
and concentrating the reinfusion volume.  
 
 51 
 
Our study has shown intra-operative cell salvage does significantly reduce transfusion 
requirements in primary THA and TKA compared to traditional rates reported in the 
literature. However we observed a substantial number of patients still required allogenic 
blood despite the use of red cell salvage. Patients undergoing THA were more likely to 
require allogenic blood. This appears to be a consequence of an increased proportion of 
THA patients with pre-operative hemoglobin less than 120g/L and potential for greater 
hidden blood loss into the thigh and buttock following THA.  
One noteworthy finding of our study is only about 60% of patients actually received 
returned red cells. Nearly half the patients did not receive back any of their own blood lost 
during surgery. It appears for cell salvage to be effective, a critical amount of blood loss is 
necessary. Processing returned red cells is an interaction of volume loss and haematocrit of 
the blood salvaged. From our data, average blood loss in the patients receiving returned red 
cells was 362mls, range 200mls to 1200mls, compared to average 156mls, range 50mls to 
350mls in the group with insufficient loss to salvage.  A minimum of 200mls intra-operative 
blood loss is required to cell salvage, dependent also on the haemaglobin of the blood lost. 
Paradoxically, anemic patients require greater blood loss intra-operatively to be able to 
utilize cell salvage effectively. This further emphasizes the importance of correcting pre-
operative hemoglobin, in our results to a minimum of 120g/L.  
 
Reflecting the above observations, in our cell salvage cohort a greater intra-operative blood 
loss and higher pre-operative haemaglobin resulted in a significantly reduced risk of 
allogenic transfusion. Patients who received returned red cell were less likely to require 
allogenic blood, confirming its protective effect. In keeping with previous literature, 
receiving allogeneic blood was detrimental to our patients’ recovery, culminating in a longer 
hospital stay and higher incidence of complications. 
 
We demonstrated patients with low hemoglobin pre-operatively were at higher risk of 
requiring allogenic blood despite the use of cell salvage, emphasizing the need to identify 
and correct pre-operative anemia prior to surgery 15,35. In our cohort, the critical 
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haemaglobin level was 120g/L, which increased the transfusion risk by 30 times compared 
to patients with haemaglobin above 150g/L. There were several non-modifiable factors, 
such as age and gender, which increased transfusion risk, highlighting the need to be 
diligent and proactive in these patient groups in correcting or optimizing other factors. 
 
Our study does have several limitations and weaknesses. Being a retrospective study 
predisposes the data to recall and selection bias. We did not have a control or comparison 
group. Instead we chose to compare our results with transfusion rates reported in the 
literature. We cannot therefore be sure our results are purely due to the use of cell salvage 
technique alone and not other factors. Care should be taken when comparing our study 
with other cell salvage studies, which may have different patient populations, cell salvage 
devices, transfusion triggers, anesthetic practices and surgical technique. We did not use a 
tourniquet when performing TKA, which increases intra-operative blood loss. However 
increasing intra-operative blood loss during TKA should increase the benefits of intra-
operative cell salvage. We also concede the use of intra-articular drains has now been 
shown to increase transfusion risk and a drain in TKA is often no longer routinely used. 
Recent studies have focused on hemostatic agents such as tranexamic acid, showing 
excellent effectiveness in reducing blood requirements following both THA and TKA 36,37,38. 
Our study cohort did not receive any form of tranexamic acid, which has now become 
common practice in joint arthroplasty. Additionally, our patients continued aspirin during 
the peri-operative period in the belief this would be cardio-protective. However a recent 
large randomized controlled trial of 10010 patients of which 39% underwent orthopaedic 
procedures, comparing aspirin versus placebo with 30 days follow up after surgery, found 
contradictory results 39. There was no difference in the primary outcome of death or 
myocardial infarction between the 2 groups, regardless of whether the patient was taking 
aspirin prior to surgery or not. Aspirin increased the risk of major bleeding compared with 
placebo. The authors concluded aspirin administration before surgery and throughout the 
early postsurgical period had no significant effect on the rate of a composite of death or 
nonfatal myocardial infarction but increased the risk of major bleeding. We no longer 
routinely continue aspirin unless absolutely necessary. 
 53 
 
Nevertheless, we believe our study retains relevance as cell salvage remains one of a 
number of options available in a blood management strategy and is still commonly used. It 
is relatively simple to implement into the surgical algorithm and can be combined with other 
modalities. Our study was a consecutive series with sufficient numbers to be able to deduce 
several important conclusions. 
Avoiding allogenic blood following THA and TKA has taken on increased significance due to 
the escalating cost of blood banking and stored blood. Therefore, intra-operative cell 
salvage should be incorporated in a comprehensive blood management strategy. Whilst cell 
salvage is effective in reducing allogenic blood requirements, other strategies should be 
used in combination, including maximizing pre-operative hemoglobin, using appropriate 
antifibrinolytic agents such as tranexamic acid and individualizing the transfusion trigger. 
The ultimate aim is allogenic blood requirement in elective THA and TKA should be zero. 
 
Conclusion 
 
Intra-operative cell salvage reduces but does not eliminate the need for allogenic blood 
transfusion following primary THA and TKA. A critical amount of intra-operative blood 
volume loss of 200mls and pre-operative hemoglobin above 120g/L is required for cell 
salvage to be effective. Future studies are required to define the ideal and most cost 
effective blood management program in THA and TKA. 
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Tables 
 
Characteristic THA (n=135) TKA (n=236) Total (n=371) 
Female gender 86 (63%) 130 (55%) 216 (58%) 
Age > 75 39 (29%)   62 (26%) 101 (27%) 
Age years (mean, range) 70 (17- 91) 70 (47 – 95)   70 (17 – 95) 
BMI kg/m2 (mean, range) 27.4 (15.7 – 43.8) 30.3 (18.5 – 52.2) 29.2 (15.7 – 52.2) 
BMI category 
  <20 
  20 – 25 
  >25 – 30 
 >30 
 
  3 (2%) 
47 (35%) 
45 (33%) 
40 (30%) 
 
    1 (<1%) 
  30 (13%) 
  98 (42%) 
107 (45%) 
 
    4 (1%) 
  77 (21%) 
143 (39%) 
147 (40%) 
Diagnosis 
  Osteoarthritis 
  Inflammatory 
  Other 
 
119 (88%) 
    2 (1%) 
  14 (10%) 
 
230 (97%) 
    4 (2%) 
    2 (1%) 
 
349 (94%) 
    6 (2%) 
  16 (4%) 
Pre-op Hb g/L (mean, 
range) 
134 (72 – 170) 138 (103 – 177) 137 (72 – 177) 
Pre-op Hb category 
  >= 150g/L 
 >=120 – 150 g/L 
<120 g/L 
 
20 (15%) 
95 (70%) 
20 (15%) 
 
  63 (27%) 
162 (69%) 
  11 (5%) 
 
   83 (22%) 
 257 (69%) 
   31 (8%) 
 
Table 1. Demographics of the study population.  
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Study Bierbaum 1 del Trujilo 24 Smith 25 Moonen 26 Our Data 
Allogenic 
Transfusion 
Rate 
 
57% 
 
15% 
 
8% 
 
6% 
 
23.7% 
 
Table 2. Effects on Allogenic Transfusion Rates of autologous re-transfusion of salvaged blood cells in 
randomized controlled trials and cohort studies for THA compared to historical rate reported by 
Bierbaum without intervention. 
 
 
 
Study Bierbaum 1 Shenolikar 27 Thomas 28 Munoz 40 Our Data 
Allogenic 
Transfusion 
Rate 
 
39% 
 
16% 
 
7% 
 
11% 
 
11.9% 
 
Table 3. Effects on Allogenic Transfusion Rates of autologous re-transfusion of salvaged blood cells in 
randomized controlled trials and cohort studies for TKA compared to historical rate reported by 
Bierbaum without intervention. 
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Outcome THA (n=135) TKA (n=236) Total (n=371) 
Transfused 32 (24%) 29 (12%) 61 (16%) 
Whole blood loss mL 
(mean, range) 
271 (50 – 1200) 290 (100 – 950) 283 (50 – 1200) 
Red cells returned 79 (59%) 149 (63%) 228 (61%) 
Volume cell salvaged 
(mL)‡ 
205 (40 – 890) 193 (10 – 650) 197 (10 – 890) 
Hb loss to day 0* g/L 
(mean, range) 
17.7 (-34 – 40) 18.7 (-12 – 47) 18.3 (-34 – 47) 
Hb loss to day 1** g/L 
(mean, range) 
27.3 (-29 – 53) 29.1 (6 – 56) 28.4 (-29 – 56) 
Knee drain volume mL 
(mean, range) 
--- 209 (0 – 800) --- 
Any surgical 
complication 
29 (21%) 45 (19%) 74 (20%) 
Days to discharge 
(mean, range) 
6 (3 – 16) 6 (3 – 30) 6 (3 – 30) 
* Pre op Hb minus day 0 post op Hb 
** Pre op Hb minus day 1 post op Hb 
‡ In those with cell salvage only (n = 228) 
Table 4. Transfusion, blood loss and outcomes for THA, TKA and combined cohort of patients. 
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Characteristic Cell Salvage Status Mean Difference 
(95% CI) 
p-value 
Outcome Yes No   
Pre-operative Hb 
[g/L; mean (SD)] 
137.40 
(14.03) 
135.85 
(12.76) 
1.6 
(-1.4- 4.5) 
0.30 
Blood Loss 
[mL; mean (SD)] 
362.48 
(136.69) 
156.15 
(52.06) 
206.3 
(182.8- 229.8) 
<0.001 
 
Table 5. Comparison of pre-operative haemaglobin and intra-operative blood volume loss according 
to patient cell salvage status.  
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Outcome Transfused 
(n=61) 
Not Transfused 
(n=310) 
Total  
(n=371) 
Difference  
(95% CI)§ 
p-value§ 
Pre-operative Hb. 
[g/L; mean (SD)] 
122.76 
(14.26) 
139.61 
(11.54) 
136.80 
(13.56) 
-16.9 
(-13.5- -20.2) 
<0.001 
Whole blood loss   
[mL; mean (SD)] 
245 (156) 290 (148) 283 (150) -45.6  
(-4.4- -86.8) 
0.03 
Red cells returned 
[count (%)] 
29 (48%) 199 (64%) 228 (61%) -16%  
(-3%- -30%) 
0.02 
Volume cell salvaged  
[mL; median (IQR)] 
156 
(130 - 270) 
150  
(135 - 250) 
150  
(135 – 250) 
6 (N/A) 0.40 
Hb loss to day 0*  
[g/L; mean (SD)] 
19.3 (13.2) 18.1 (8.2) 18.3 (9.3) 1.2 () 0.38 
Hb loss to day 1**  
[g/L; mean (SD)] 
28.4 (16.2) 28.5 (8.4) 28.4 (10.1) -0.1  
(-3.0- 2.8)  
0.95 
Post-op Hb Day 1 
[g/L; mean (SD)] 
103.46 
(11.04) 
121.65 
(12.60) 
118.46 
(14.14) 
  
Knee drain volume  
[mL; mean (SD)***] 
205  
(162) 
210 
(170) 
209  
(169) 
-4.8  
(-73.4 - 63.7) 
0.89 
Time to discharge  
[days; median (IQR)] 
6 (5 - 8) 5 (5 - 7) 5 (5 - 7) 1 (N/A) 0.01 
Any surgical complication 
[count (%)] 
29 (48%)   45 (15%)   74 (20%) 33%  
(20% – 46%) 
<0.001 
§ 95% confidence intervals and p-values are for the difference between transfused and not transfused groups 
*** in 27 transfused patients and 197 non-transfused patients with knee surgery 
Table 6. Comparison of blood loss and outcomes for patients who received allogenic blood 
transfusion and patients who were not transfused.  
Univariable analysis 
Risk factor  Odds ratio 95% C.I. P-Value 
Female gender 3.5 1.8 – 6.8 <0.001 
Age >75 5.2 2.9 – 9.2 <0.001 
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Procedure - hip*  2.3 1.3 – 4.0 0.004 
Diagnosis inflammatory**  1.2 0.1 – 10.1 0.75 
Diagnosis other**  4.62 1.74 – 12.28 0.002 
Hb <120 g/L*** 44.4 12.8 – 154.3 <0.001 
Hb >=120 <150 g/L*** 2.5 0.8 – 7.3 0.21 
BMI < 20 **** NA NA NA 
BMI >25 – 30 **** 0.34 0.17 – 0.67 0.002 
BMI >30 **** 0.23 0.11 – 0.48 <0.001 
Multivariable analysis 
Risk factor  Odds ratio 95% C.I. P-Value 
Female gender   2.8 1.2 – 6.6 0.02 
Age >75   5.9 2.9 – 12.1 <0.001 
Hb <120*** 30.1 7.5 – 121.6 <0.001 
Hb >120 <150 g/L***   1.3 0.4 – 4.1 0.32 
* Compared with knee replacement 
** Compared with diagnosis = osteoarthritis 
*** Compared with Hb >150g/L group. 
**** Compared to ‘normal’ BMI category of 20 – 25 
Table 7. Univariable and multivariable analysis of risk factors for allogenic blood transfusion with the 
use of intra-operative red cell salvage.  
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Discussion 
The aim of this thesis is to identify what are the optimal methods for reducing blood loss in 
total joint surgery, specifically knee and hip arthroplasty. 
 
Through review of the current best practice guidelines for blood management in surgery by 
the National Blood Authority of Australia I was able to identify areas considered best 
practice lacking evidence with regard to total joint arthroplasty. These included; 
 
1) Avoiding hypothermia in surgery. There was no evidence for this in knee replacement 
surgery. My first paper addressed this. 
2) Cell Salvage. Currently available studies in arthroplasty involve small numbers and it was 
unclear which population of patients benefited from it’s use as according to the national 
blood authority guidelines. My second paper addressed these issues 
 
Each paper individually describes and discusses the strengths and weaknesses of each 
paper’s findings separately. This discussion therefore aims to expand, and not repeat the 
individual discussion of each paper. 
 
 
Relation to other research 
1) Blood loss in primary total knee arthroplasty—body temperature is not a 
significant risk factor—a prospective, consecutive, observational cohort study? 
This is the first paper to look at temperature and its association with blood loss in total knee 
arthroplasty. Our paper demonstrated that temperature variations do not have a significant 
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association with blood loss in total knee arthroplasty. Our study differs from hip 
arthroplasty where previous studies have reported even mild hypothermia (<10 C) 
significantly increases surgical blood loss by approximately 16% and the relative risk of 
transfusion by 22%cliii. As a result of our study, resources should be spent on other areas to 
prevent blood loss in TKA. Other factors were shown to be significant for blood loss: age, 
surgical technique, anaesthetic type and type of anticoagulant medication used for DVT 
prophylaxis. 
 
Computer navigation has previously been demonstrated to produce reduced blood losscliv,clv], 
as a consequence of the femoral and tibial intramedullary canals not being violated. 
Another major difference in surgical technique was the use of hybrid prostheses by surgeon 
A (femoral component uncemented) and fully cemented prostheses by surgeon B. Blood 
loss has not been found to be associated with prosthesis type in terms of cement vs 
cementless fixation in TKA previously, and given the variables in our paper, we are not in a 
position to answer this question clvi. 
Already demonstrated in hip arthroplastyclvii  this is the first study to show a protective 
effect of regional and spinal anaesthesia in total knee arthroplasty against transfusion. 
Regional anaesthesia results in decreased arterial blood pressure clviii , whilst spinal 
anaesthesia leads to venous hypotension and a decreased venous pressure at the surgical 
site clix. 
Regarding bleeding and choice of thromboprophylaxis our results differ with that from 
larger clinical trials of rivaroxaban and enoxaparin, given we found higher bleeding with 
rivaroxaban than with enoxaparinclx. Patients continuing warfarin with an INR of 2 on the 
day of surgery was associated with a lower drain volume than patients treated with low 
molecular weight heparin and rivaroxaban. The practice of continuing coumadin without 
cessation in patients already taking the medication pre-operatively or in patients with 
previous history of pulmonary emboli was utilised by both surgeons and supports a growing 
trend that peri-operative bridging therapy and coumadin cessation may not be necessary or 
the most effective strategy in patients undergoing TKA clxi . See appendix ii) further 
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information on a study I was involved in. Again while I was an author, it is not my original 
work and therefore is not included within the thesis. 
 
2) Analysis of the effectiveness of perioperative cell salvage in primary total hip 
and knee arthroplasty 
There are a number of randomised control trials for cell salvage techniques. Our aim was to 
show a reduced transfusion rate in our population. This has been proven previously in three 
randomised control trials. Our other aim was to analyse this population of patients 
(arthroplasty) and better define who received benefit from the use of the cell saver(i.e. did 
not need transfusion). 
 
We found hip patients were more likely to require allogeneic blood mostly likely due to the 
greater potential for hip patients to have hidden blood loss in the post-operative period into 
the thigh and buttock. Patients with low hemoglobin pre-operatively were also at higher risk, 
emphasizing the need to identify and correct pre-operative anaemia prior to surgery. Whilst 
we also identified non-modifiable factors such as age, gender and hips, and this highlights 
the need to be more diligent in these patient groups in correcting or optimizing other 
factors. These findings are consistent with Bierbaum’s historical paperclxii. 
 
We were also able to demonstrate the adverse consequences of being transfused. Those 
transfused in our study had a statistically significantly longer hospital stay and higher 
incidence of post-operative complications. Allogeneic transfusion has been shown to be 
detrimental to patient outcome and recovery following joint replacement surgery. In an 
elective arthroplasty setting, it has been shown in a prospective study involving 444 patients 
that transfusion is associated with an increased risk of wound infection, and subsequently 
an increased length of hospital stay in patients undergoing total hip arthroplastyclxiii. In a 
hemi-arthroplasty group of 290 patients transfusion appeared to be correlated with 
superficial wound infection, urinary infection and pneumoniaclxiv. Another retrospective 
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study of 2,104 total hip arthroplasty patients showed red blood cell transfusion to be an 
independent risk factor for length of stay regardless of hemoglobin differenceclxv. 
 
Significantly where our study expanded the literature was understanding and identifying 
patients with a pre-operative haemoglobin of 120-150 as likely to benefit most from cell 
salvage. The amount of blood loss required for the red cell salvage process and be returned 
as blood to the patient is a complex interaction between volume loss and the hematocrit of 
the blood lost. Paradoxically, anaemic patients pre-operatively have to lose more blood 
intra-operatively to be able to cell salvage. If the haematocrit is low this will mean that it 
requires a greater volume of salvaged blood to produce a given number of packed cells for 
re-infusion into the patient. This means if the patient commences the operation with a low 
hemoglobin they will have to lose even more blood to have enough red cells to be able to 
returned the patients than those with a high hemoglobin and it becomes ever more likely 
that they will then need a blood transfusion. Patients with a haemoglobin of >150  are 
unlikely to require cell salvage to prevent allogeneic transfusion. Those with a preoperative 
haemoglobin of <120 should undergo measures to increase preoperative baseline 
haemoglobin. This will not only decrease their risk of transfusion, but also improve the 
effectiveness of cell saver in this population by allowing a higher haematocrit of reinfused 
cell salvage red blood cells. 
 
Challenges 
 A key area of learning from conducting this research was the recognition of the fallibility of 
our methods for estimating intra-operative blood loss. These methods should have been 
best reviewed in greater detail prior to conducting the research in the methods section of 
the thesis. However it was only after conducting the research that inaccuracies in our 
measurements became apparent. The challenges that we experienced in this research when 
the literature was interrogated in more detail are not unique and perhaps represent the 
challenge that is implicit in trying to make the operating theatre a precise research 
laboratory.  
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Blood loss measurement 
--- Intraoperative blood loss measurements 
 
Given the wide range of values (including negative values), our methods for determining 
intraoperative blood loss was deemed inaccurate. 
A number of methods for calculating intra-operative blood loss exist, including; visual 
estimation, direct measurement, weight, photometry and other miscellaneous methods 
 
- Quick and non-labour intensive; visual estimates has been shown to be a poor 
representation of actual blood loss clxvi and when used in clinical practice, visual estimation 
often leads to poor transfusion practicesclxvii 
Direct measurement best describes our method of collection. Collecting blood into a 
container, in our case the suction container. It, however, is contaminated by other fluid 
sucked up such as synovial fluid, irrigation fluid, and misses blood absorbed by gauzes and 
swabs, on drapes and spilt onto the floor. Without some estimation or measurement of 
these losses, this method may be inaccurate. 
 
Weighing blood by collecting all contaminated surgical drapes, linen, towels, or gauze and 
then deducting the dry weight of the items. This method requires an accurate scale and is 
labour intensive. It also does not discriminate between other fluids contributing to the 
contaminated weight, such as irrigation fluid. This method has been proven to be an 
accurate method.clxviii 
 
Photometry involves dissolving blood from absorbent theatre material to alkaline haematin 
with measurement of the optical density to determine intraoperative blood loss, which has 
been shown to have accuracy within 10% of actual blood lossclxix. It is far more labour 
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intensive and expensive given the equipment and qualified individuals required to utilise 
this method. 
 
Notable miscellaneous techniques include ultrasound measurement of superior vena cava 
volume and radiographic red cell labelling. These are not practical currently. 
 
---Calculating total blood loss 
We used haemoglobin for total blood loss given it is our clinical reference in everyday 
practice as doctors/surgeons. However, using haemoglobin as measure for blood loss 
assumes a constant total blood volume, and is therefore only an estimation of true blood 
loss. Several formulas have been developed to calculate total blood loss. 
 
Blood volume (PBV) can be calculated using the formula of Nadler, Hidalgo and Blochclxx: 
PBV = kl x height (m)3 + k2 x weight (kg) + k3 
where kl = 0.3669, k2 = 0.03219, k3 = 0.6041 for men; 
kl = 0.3561, k2 = 0.03308, k3 = 0.1833 for women 
 
Multiplying the haemocrit against the blood volume will give the total red cell volume. As 
such ; 
 
Brooke first described blood loss as a logarithmic function.clxxi 
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Hct0= preoperative value and t= final haemocrit post operatively 
 
‘Gross formula’ uses average haematocrit to reflect the linear change that is isovolumetric 
haemodilution (as blood volume falls, fluid shift to maintain intravascular volume), and how 
average haematocrit reflects thisclxxii 
 
 
Gross validated his formulae in arthroplasty surgery. 
 
Meunier calculated a formula involving haemoglobin based off blood donors. However, it 
was concluded that haemoglobin underestimates blood loss due to time taken for 
haemodilution. clxxiii 
 
--- Calculating post operative blood loss 
In both our studies we used post operative drain volume to reflect post operative blood loss. 
This ignores residual blood in the joint, hidden blood loss into the surrounding soft tissues, 
and fails to account for blood loss due to haemolysis. As such Sehat et al developed a 
formula to more accurately calculate hidden blood loss.  
 
The hidden loss can then be determined by subtracting the visible loss from the calculated 
true total loss, then adding the volume re-infused or transfused. The results were converted 
to whole blood volume for each patient, again using their average haematocrit.  clxxiv 
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---Reflection of other blood loss measurement methods and if should they have been utilised 
in our studies 
 
The paper on cell saver focused on analysing cell saver in preventing transfusion and 
identifying risk factors for transfusion in a arthroplasty population, based on separating the 
population into transfused vs non transfused cohort. Intraoperative blood loss was 
accurately calculated utilising cell saver volume. Quantifying blood loss using other methods 
would not have affected the cell saver reinfused volume and therefore would not have 
added greater utility to our study. Haemoglobin is the utilised clinical transfusion trigger 
along with patient evaluation. 
 
In contrast the study analysing temperature and blood loss in knee arthroplasty focused on 
blood loss and not transfusion. Therefore more accurate measures to quantify the three 
areas of blood loss should have been utilized. Our intraoperative method should have 
accounted for blood loss to other areas (e.g. gauze), our total blood loss would have been 
more accurate with the Gross formula and our post operative blood loss should have taken 
into account hidden blood loss. 
 
Temperature  
Temperature is not a constant variable. It naturally changes with time, during a day with 
circadian rhythm, varies from day to day, for example with ovulation in females. It also 
changes based off metabolic state, activity levels, and as we age we are unable to produce 
extremes of temperature. The external environment also causes changes in temperature via 
the external temperature and our external clothing as a response. While normal 
temperature is stated as having a normal range of 36.5- 37.5 °C, it has been shown to have a 
much wider variation in a review of the literature.clxxv  
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What is a normal temperature also varies on the method used to measure it. Pulmonary 
wedge catheter measurements are the gold standard for measuring temperature. Rectal, 
vesical, vaginal are more invasive ways of measuring temperature. Tympanic, oral and 
axillary are less invasive. Axillary and oral temperatures typically measure a lower 
temperature than the other methods which are estimates of core body temperature.clxxvi 
 
Theatre temperature was recorded to see if it had an effect on body temperature, however, 
we were unable to show this. All other external factors contributing to patient temperature 
were difficult to record, e.g. blankets, warmed fluids as mentioned in the section difficulties 
of the operating theatre as a laboratory. 
  
As acknowledged in our study, it was extremely difficult to account for variations in 
temperature and external factors contributing to it. However, given it was an observational 
study, we did our best to monitor for changes by measuring at different time points and 
using the most reproducible non invasive temperature assessment- axillary temperature. 
Our results therefore accurately reflect real clinical practice. 
 
Data collection 
The Cell saver paper was the largest analysis of an arthroplasty cohort utilising the cell saver. 
The Data was reviewed retrospectively. Data collection and entry was exhaustive and labour 
intensive. For each subject of the cell saver paper it required 45-60 minutes to complete, as 
the recorded admission information was incomplete and other databases, such as the 
pathology results database, had to be interrogated to find missing data. Furthermore, local 
General Practitioners were contacted as an additional resource for finding missing data. 
 
Given the data was retrospective and a large volume to review, selection and recall bias 
clouds our results, mainly for the post operative complications. This means that although 
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one would think that retrospective data collection might be easier, my own experience from 
these two studies was that I suspect the retrospective data was actually more challenging 
and the final information was less robust because of it. 
 
Comparing this to prospective data collection used in the temperature study, my chart 
review time was minimal. A form was designed and placed on the patients chart from time 
of admission to discharge to allow for the necessary data to be recorded by the surgical 
fellow of Dr Liu and Randle at the time. However when reviewing the data for statistical 
analysis it was clear that not all forms were filled out correctly, at times with missing and 
incorrect data. The data form was often completed by nursing staff, when the fellow was 
not available. Selective retrospective review of admission charts was needed to find missing 
data and adjust some input at times. We suffered from attrition and change in methods bias 
that is typical of prospective studies. Training of research assistants would have improved 
the quality of the information collected.  
 
Human based research 
Experimenting on humans brought limitations to our study. Given the patients were from a 
private hospital there was a further expectation not to intervene in these patients. A side 
aim of this research might be the effort required to also evaluate one’s own clinical work 
would hopefully lead to an improvement in the quality of what was being done. I think this 
misconception that research is something best left to the public sector is misconceived-and 
our study is evidence of benefit to practice by evaluation of this private sector group of 
patients.  
 
However studies had to be designed in line with current treatment practice the same as a 
patient that was not in the study would receive.  
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While temperature and blood loss had never been explored in knee arthroplasty, other 
areas of surgery had showed a detrimental effect with increased blood loss in hypothermic 
patients. Given best practice guidelines advised against hypothermia it could not be justified 
to actively lower a knee replacement patient’s temperature to separate the two arms of the 
experiment. This only allowed us to do an observation study. We therefore required more 
patients in the study as the majority of temperatures lay within the middle range in 
between the low temperature group and normothermic group. 
 
In the cell saver population, there wasn’t a direct comparison group from the same surgeon 
and as a result historical literature had to be referred to as the comparator, which has 
inherent statistical problems by comparing different populations. 
 
It also meant extra efforts had to be made with storage and entry of data to protect patient 
confidentiality. 
 
On a plus side observing current treatment and with differing outcomes meant our results 
were directly applicable to and able to give great insight into current clinical practice! 
 
Operating theatre as a laboratory 
Few practices in surgery are evidenced based instead they are largely historical. General 
surgery has 50% the evidence based practice compared with internal medicineclxxvii. This is 
complicated by the rapid development of surgical treatments confounded by the historical 
post anaesthetic discovery period and the commercial interests guiding decision making 
processes and developmentclxxviii.  
 
New techniques are subject to the surgeon’s learning curve, practice effect reflecting higher 
complications when a new procedure is undertaken by a surgeon compared with a stable, 
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previously used technique. Given Dr Liu and the local hospital preference was to use cell 
saver in all patients, this made the study a historical control study, which can overestimate 
the benefits of an intervention due to other advances in the field over time. clxxix 
 
The challenges of trials in surgery have previously been documented. They largely relate to 
the difficulties in comparing treatment options in surgery, due to innate surgical ability and 
decision making varying between surgeons and patient selection for operation (along with 
different patient groups) differing, making randomisation difficult clxxx.  
 
This was evident in our first study on temperature and blood loss in total knee arthroplasty 
whereby the individual surgeon was found to be a large influence on blood loss. While all 
variables were recorded and compared with multivariable analysis, this has no doubt 
reduced the ability of the study to examine specifically the effect of body temperature on 
blood loss due to confounders. 
 
Differing patient populations have different characteristics. We tried to best account for this 
through multivariable analysis of demographic and physiological characteristics. 
 
Patients had different comorbidities, often on different medications (specifically aspirin, 
clopidogrel and warfarin), and receiving different anaesthetic if one form was 
contraindicated because of a comorbidity or antiplatelet medication. Again these were 
accounted for with multivariable analysis. 
 
Surgeons had different practice variations- as explored in the temperature study we found a 
difference in blood loss between surgeons. Again we tried to account for these by 
multivariable analysis including the surgeon and thromboprophylactic medications. 
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The cell saver paper was a single surgeon paper and removed the influence of differing 
practice to the results. 
 
The more humans involved in a study leads to  an increased chance of human error with 
results. Issues with data collection as discussed above reflect this. 
 
Overall while an imperfect laboratory, we sort clinical answers from a real time clinical 
environment. The clinical setting is not a controlled experimental laboratory setting, but is 
based on variable doctor, patient and environmental factors. Multivariable analysis helped 
us reduce confounding variables influencing results, while still gaining clinically relevant 
results. 
 
Future directions/implementation strategy 
By submitting the articles to peer reviewed journals and presenting the studies at national 
and state orthopaedic meetings it was hoped the evidence is delivered to orthopaedic 
arthroplasty surgeons in an appropriate manner to allow them to change practice as 
accordingly seen fit. 
 
The results generated from the masters project will help develop best practice guidelines 
more specific to arthroplasty surgery than the current national blood authority of Australia’s 
guidelines. Dr David Liu, my clinical supervisor, was invited to write a review article on the 
topic of blood management in arthroplasty surgery. 
 
While the results from my studies helped generate a basis for this review article, it is not my 
original work, and as such is included in the appendix and not the main document. See 
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appendix iii) Liu D, Dan M, Adivi N. Blood Conservation Strategies in Total Hip and Knee 
Arthroplasty. Reconstructive review. 
 
The article highlights the importance of patient specific blood management strategies, 
aiming to conserve blood in three areas i) pre operatively, ii) intra-operatively, iii) post 
operatively. Specific mention was made to highlight the importance of identifying and 
correcting pre-operative anaemia, salvaging peri-operative red cells and the use of 
tranexamic acid in reducing blood loss. The below table summarizes conservation strategies 
in these three areas. 
 
Pre-operative  Intra-operative Post-operative 
1. Correcting anaemia 
   a) Iron supplements 
   b) Erythropoietin 
2. Pre-operative autologous 
blood donation 
3. Ceasing antiplatelet and 
anticoagulant medications 
1. Acute normovolaemic 
haemodilution 
2. Intra-operative cell 
salvage 
3. Tranexamic acid 
   a) Intravenous 
   b) Topical 
   c) Oral 
1. Post-operative cell salvage 
2. Re-infusion drain 
3. No drain use 
4. Tranexamic acid 
   a) Intravenous 
   b) Oral 
 
Blood management strategies are individualised based on each patient and surgeon factors. 
Therefore, it is up to the surgeon to assess each of their patients and decide how these 
recommendations best relate to their patients and practice. 
 
Personal development 
Doing the masters has helped me develop in a number of ways; 
---Personal attributes-  
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My ability to time manage has significantly improved. Having to manage full time work as a 
doctor, family commitments and social life while undertaking this masters has been difficult 
and at times not manageable. I quickly learnt to set myself deadlines and work towards 
goals. Once I had achieved each goal, I had to quickly reset new ones to make the most of 
my time. 
 
---Research abilities.  
Undertaking the masters has enabled me to participate and understand the process of how 
to conduct a study. Defining a question, undertaking a literature search and review, study 
design, gaining ethics approval, data collection, statistical analysis, writing up the research 
and multiple refinements for publication and presentation. I am now in a position to be 
more efficient with my time for future research, and by engaging in research, I will be better 
able to critique other evidence based medicine 
---Doctor/surgeon.  
Through undertaking research in my chosen field, orthopaedics, I have been able to gain a 
better knowledge base in the field I want to practice. This has helped with the way I treat 
my patients by allowing me to practice and advocate for best evidence medicine/surgery. 
 
 
Conclusion 
Arthroplasty, or joint replacement surgery, is increasing in incidence with an ageing 
populationclxxxi. An older age is associated with a lower baseline haemoglobin. These are the 
two highest risk factors for allogenic red cell transfusion in arthroplasty surgeryclxxxii. Given 
the number of surgeries are increasing, and the patient group are at increased risk, 
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measures need to be taken to reduce the overall incidence of red cell transfusion as 1) 
allogenic blood is a limited resource and 2) allogenic transfusion are associated with a 
impaired outcomes in the arthroplasty population. 
 
This thesis What are the optimal methods for reducing blood loss in total joint surgery 
sought to better understand this health care challenge. Through the literature review I was 
able to find additional evidence for recommendations in the national blood authority’s 
perioperative guidelines for blood managementclxxxiii as it related to arthroplasty and was 
able identify areas where the recommendations lacked evidence from an arthroplasty 
perspective, and this formed the basis of the two papers. 
 
Blood loss in primary total knee arthroplasty—body temperature is not a significant risk 
factor—a prospective, consecutive, observational cohort study? Was the first study to look 
at temperature and its relationship to blood loss in knee arthroplasty, and contrary to other 
areas of surgery it was not associated with blood loss in the knee arthroplasty patient. 
Significantly it was the first study to demonstrate the protective benefit of regional and 
spinal anaesthesia in preventing blood loss in knee arthroplasty patients. 
 
Analysis of the effectiveness of perioperative cell salvage in primary total hip and knee 
arthroplasty explored the use of cell saver in the largest cohort of arthroplasty patients in 
the literature to better define its utility. We identified low haemoglobin(<120) as having he 
highest odds of transfusion and a high haemoglobin(>150) as having minimal odds of 
transfusion, and as such are unlikely to need cell saver to prevent transfusion. The amount 
of blood loss required for red cell salvage to utilize the returned blood is an interaction of 
the total volume of blood loss and the hematocrit of the blood lost. Paradoxically, anaemic 
patients pre-operatively have to lose more blood intra-operatively to be able to cell salvage 
and this could contribute further to low haemoglobin and being at increased risk of 
transfusion. Therefore we believe those with a hemoglobin of 120-150 are likely to receive 
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the greatest utility from cell saver and those with a hemoglobin of <120 should undergo 
measures preoperatively to increase their baseline hemoglobin prior to surgery. 
 
This evidence helps to contribute to formulating a blood management program in patients 
undergoing arthroplasty to decrease allogenic transfusion rates through pre, intra and post 
operative measures. Clinicians are encouraged undertake these practices due to the 
evidence behind it.  
 
As arthroplasty is an elective procedure, we should aim for a zero complication rate. 
Anaemia due to blood loss is one of the major complications of arthroplasty surgery, 
additionally to that; blood loss and allogenic transfusion further contribute to other 
perioperative complications. As addressed by this thesis, all such measures should be taken 
to minimise this blood loss and allogenic transfusion. 
 
 
 
 
 
 
 
 
 
List of tables, figures, diagrams, illustrations 
Each of the tables and figures are presented in the respective papers section. They have no 
independent value and are therefore not represented here. 
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Appendix i) 
Surgeons 
Dr David Liu- involved in both studies.  
Dr Ray Randle- involved in only the temperature study involving Total Knee arthroplasty. 
 
Location 
Both surgeons operate at the John Flynn private hospital in Tugan on the Gold Coast, 
Queensland. Near identical operating theatres and similar perioperative staff and protocols, 
including operating room temperature of 19-20 degrees. 
 
Hip Replacement-  
-Only used in the cell saver paper by Dr Liu 
 
Approach- Dr Liu utilises an anterio-lateral approach to hip for his total hip arthroplasty. 
The patient is placed in the lateral position. The skin incision 2.5 cm posterior and distal to 
ASIS continued distally centred of tip of greater trochanter and continuing over the 
posterior 1/3rd of the femoral shaft. 
 94 
 
                                                                                                                                                                                    
 -Superficially the fascia lata is split and a plane is developed between gluteus 
medius and tensor fascia lata 
  -Deep dissection involves partial splitting of the abductor mechanism . The 
leg is externally rotated and and anterior capsulotomy is performed to expose the hip joint. 
Rectus femoris and iliopsoas are reflected off the joint capsule as needed 
  -The femoral neck is sawed off, acetabulum exposed. The acetabulum is 
reamed to expose bleeding subchondral bone. The acetabulum shell and cup are then 
placed in a slightly anteverted(approximately 10⁰) and abducted position(40⁰). 
   -The femoral canal is then broached to appropriate size and femoral neck and 
head are able to ensure adequate offset and range of motion without risk of impingement 
or dislocation. 
 
Components: Uncemented acetabular and femoral components were inserted in all 
patients. 
 
Wounds were closed in a layered fashion, including capsule repair, without use of a 
drain. 
Patients were allowed to immediately weight bear post operatively 
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DVT prophylaxis- All patients received enoxaparin 40mg daily for venous 
thromboembolic prophylaxis, commencing 4 hours post-operatively and continued for 28 
days. 
   -All patients received mechanical prevention in the form of T.E.D. 
(Thrombo Embolic Deterrent) stockings and while non-ambulatory sequential compression 
devices (SCD). 
 
No patient received tranexamic acid, as these studies were carried out prior to its routine 
use. 
 
Knee replacement 
-Utilized by both surgeons. 
 
Approach: Both surgeons utilise a medial parapatellar approach, with the patient in the 
supine position. The skin incision is midline proximal to the patella, across its midline, down 
the medial aspect of the tibial tubercle. 
Superficial dissection involves incising and reflecting subcutaneous fat and deep fascia. 
Deep dissection involves splitting between vastus medialis and vastus intermedius tracing 
distally 1-2cm medial to the patella tendon through the retinaculum to expose the joint, 
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down to the medial side of the tibial tubercle. The patella tendon is inverted and retracted 
laterally to expose the joint. 
 
   
Dr Liu utilises computer navigation for femoral and tibial bone cuts and component position 
where as Dr Randle utilises intramedullary instrumentation for femoral and tibial bone cuts. 
 
Components- Both surgeons resurface the patella in all cases 
 
Tourniquet-  is not used by either surgeon 
 
Wounds were closed in a layered fashion with the use of an intra-articular drain removed 
day 1 post operatively in all cases by both surgeons. 
   
Both surgeons allowed patients to weight bear immediately post operation. 
DVT prophylaxis- Dr Liu- All patients received enoxaparin 40mg daily for venous 
thromboembolic prophylaxis, commencing 4 hours post-operatively and continued for 14 
days. 
 97 
 
                                                                                                                                                                                    
-Dr Randle- all patients received rivaroxaban 10mg daily initiated 6 hours post operation and 
continued for 14 days. 
Aspirin was continued in those patients on it pre operatively along with enoxaparin or 
rivaroxaban. Patients on warfarin preoperatively were continued on this as the choice of 
chemical DVT prophylaxis at a perioperative INR of 2.2. 
All patients received mechanical prevention in the form of T.E.D. (Thrombo Embolic 
Deterrent) stockings and while non-ambulatory sequential compression devices (SCD). 
 
No patient received tranexamic acid, as these studies were carried out prior to its routine 
use. 
 
Observations and investigations 
Routine 6 hourly observations were utilized for the temperature study. As this study was 
observational no change was needed. Temperature was measured using axillary 
temperature. 
 
Total drain volume was routinely measured by nursing staff and translated to post operative 
blood loss in knee replacement patients 
 
 98 
 
                                                                                                                                                                                    
Routine Blood tests including a full blood count and electrolytes was routinely carried out 
within 2 weeks prior to the operation and day 1 following the operation. This allowed a pre 
operative vs post operative difference in haemoglobin to be calculated correlating with total 
blood loss. 
 
Anaesthetic agents- 
Where possible regional block(femoral) and spinal were utilised in combination with a 
general anaesthetic or sedation. Patient preferences, comorbidities or failed attempts at 
spinal lead to different combinations regional, general and spinal being utilised. These were 
recorded 
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